annual cash & cash equivalents:
$7.62B+$720.00M(+10.44%)Summary
- As of today (May 29, 2025), ABT annual cash & cash equivalents is $7.62 billion, with the most recent change of +$720.00 million (+10.44%) on December 31, 2024.
- During the last 3 years, ABT annual cash & cash equivalents has fallen by -$2.18 billion (-22.28%).
- ABT annual cash & cash equivalents is now -59.10% below its all-time high of $18.62 billion, reached on December 31, 2016.
Performance
ABT Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$6.53B-$1.08B(-14.23%)Summary
- As of today (May 29, 2025), ABT quarterly cash & cash equivalents is $6.53 billion, with the most recent change of -$1.08 billion (-14.23%) on March 1, 2025.
- Over the past year, ABT quarterly cash & cash equivalents has increased by +$248.00 million (+3.95%).
- ABT quarterly cash & cash equivalents is now -64.92% below its all-time high of $18.62 billion, reached on December 31, 2016.
Performance
ABT quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ABT Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +10.4% | +4.0% |
| 3 y3 years | -22.3% | -14.9% |
| 5 y5 years | +97.3% | +93.4% |
ABT Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -22.9% | +10.4% | -33.9% | +4.0% |
| 5 y | 5-year | -22.9% | +97.3% | -33.9% | +93.4% |
| alltime | all time | -59.1% | >+9999.0% | -64.9% | >+9999.0% |
ABT Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $6.53B(-14.2%) |
| Dec 2024 | $7.62B(+10.4%) | $7.62B(+0.8%) |
| Sep 2024 | - | $7.56B(+8.2%) |
| Jun 2024 | - | $6.99B(+11.2%) |
| Mar 2024 | - | $6.28B(-8.9%) |
| Dec 2023 | $6.90B(-30.2%) | $6.90B(+2.8%) |
| Sep 2023 | - | $6.71B(-14.4%) |
| Jun 2023 | - | $7.83B(-14.5%) |
| Mar 2023 | - | $9.16B(-7.3%) |
| Dec 2022 | $9.88B(+0.8%) | $9.88B(+3.0%) |
| Sep 2022 | - | $9.59B(+7.4%) |
| Jun 2022 | - | $8.94B(+16.4%) |
| Mar 2022 | - | $7.67B(-21.7%) |
| Dec 2021 | $9.80B(+43.3%) | $9.80B(+5.3%) |
| Sep 2021 | - | $9.30B(+7.4%) |
| Jun 2021 | - | $8.66B(+7.5%) |
| Mar 2021 | - | $8.05B(+17.8%) |
| Dec 2020 | $6.84B(+77.2%) | $6.84B(+52.6%) |
| Sep 2020 | - | $4.48B(-5.9%) |
| Jun 2020 | - | $4.76B(+41.0%) |
| Mar 2020 | - | $3.38B(-12.5%) |
| Dec 2019 | $3.86B(+0.4%) | $3.86B(-5.6%) |
| Sep 2019 | - | $4.09B(+30.4%) |
| Jun 2019 | - | $3.14B(+3.8%) |
| Mar 2019 | - | $3.02B(-21.4%) |
| Dec 2018 | $3.84B(-59.1%) | $3.84B(-47.8%) |
| Sep 2018 | - | $7.37B(+140.4%) |
| Jun 2018 | - | $3.06B(-20.5%) |
| Mar 2018 | - | $3.86B(-59.0%) |
| Dec 2017 | $9.41B(-49.5%) | $9.41B(-14.6%) |
| Sep 2017 | - | $11.01B(+13.8%) |
| Jun 2017 | - | $9.68B(+11.1%) |
| Mar 2017 | - | $8.71B(-53.2%) |
| Dec 2016 | $18.62B(+272.3%) | $18.62B(+644.8%) |
| Sep 2016 | - | $2.50B(-3.0%) |
| Jun 2016 | - | $2.58B(-22.7%) |
| Mar 2016 | - | $3.33B(-33.3%) |
| Dec 2015 | $5.00B(+23.1%) | $5.00B(+59.7%) |
| Sep 2015 | - | $3.13B(-22.6%) |
| Jun 2015 | - | $4.05B(+25.5%) |
| Mar 2015 | - | $3.23B(-20.6%) |
| Dec 2014 | $4.06B(+16.9%) | $4.06B(+12.5%) |
| Sep 2014 | - | $3.61B(+1.2%) |
| Jun 2014 | - | $3.57B(+73.3%) |
| Mar 2014 | - | $2.06B(-40.7%) |
| Dec 2013 | $3.48B(-67.8%) | $3.48B(+20.6%) |
| Sep 2013 | - | $2.88B(-48.3%) |
| Jun 2013 | - | $5.57B(+27.4%) |
| Mar 2013 | - | $4.37B(-59.5%) |
| Dec 2012 | $10.80B(+58.6%) | $10.80B(+35.1%) |
| Sep 2012 | - | $8.00B(+13.4%) |
| Jun 2012 | - | $7.05B(+62.3%) |
| Mar 2012 | - | $4.35B(-36.2%) |
| Dec 2011 | $6.81B(+86.7%) | $6.81B(+34.9%) |
| Sep 2011 | - | $5.05B(+23.8%) |
| Jun 2011 | - | $4.08B(+48.8%) |
| Mar 2011 | - | $2.74B(-24.9%) |
| Dec 2010 | $3.65B(-58.6%) | $3.65B(-4.4%) |
| Sep 2010 | - | $3.82B(-11.7%) |
| Jun 2010 | - | $4.32B(+175.8%) |
| Mar 2010 | - | $1.57B(-82.2%) |
| Dec 2009 | $8.81B(+114.2%) | $8.81B(+80.7%) |
| Sep 2009 | - | $4.88B(+16.0%) |
| Jun 2009 | - | $4.20B(-13.8%) |
| Mar 2009 | - | $4.87B(+18.5%) |
| Dec 2008 | $4.11B(+67.4%) | $4.11B(+46.3%) |
| Sep 2008 | - | $2.81B(-26.0%) |
| Jun 2008 | - | $3.80B(+40.1%) |
| Mar 2008 | - | $2.71B(+10.3%) |
| Dec 2007 | $2.46B(+371.3%) | $2.46B(+28.6%) |
| Sep 2007 | - | $1.91B(+24.2%) |
| Jun 2007 | - | $1.54B(+125.5%) |
| Mar 2007 | - | $682.35M(+30.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2006 | $521.19M(-82.0%) | $521.19M(-1.0%) |
| Sep 2006 | - | $526.37M(-33.4%) |
| Jun 2006 | - | $790.90M(-66.2%) |
| Mar 2006 | - | $2.34B(-19.0%) |
| Dec 2005 | $2.89B(+136.1%) | $2.89B(+1.7%) |
| Sep 2005 | - | $2.85B(+96.6%) |
| Jun 2005 | - | $1.45B(-15.0%) |
| Mar 2005 | - | $1.70B(+39.0%) |
| Dec 2004 | $1.23B(+23.2%) | $1.23B(+51.1%) |
| Sep 2004 | - | $810.89M(-34.2%) |
| Jun 2004 | - | $1.23B(+9.6%) |
| Mar 2004 | - | $1.12B(+12.9%) |
| Dec 2003 | $995.12M(+41.3%) | $995.12M(-40.8%) |
| Sep 2003 | - | $1.68B(+55.9%) |
| Jun 2003 | - | $1.08B(+5.7%) |
| Mar 2003 | - | $1.02B(+44.9%) |
| Dec 2002 | $704.45M(+7.2%) | $704.45M(-5.1%) |
| Sep 2002 | - | $742.65M(+54.0%) |
| Jun 2002 | - | $482.14M(-49.0%) |
| Mar 2002 | - | $944.98M(+43.8%) |
| Dec 2001 | $657.38M(-28.1%) | $657.38M(+10.6%) |
| Sep 2001 | - | $594.15M(-10.6%) |
| Jun 2001 | - | $664.75M(+35.1%) |
| Mar 2001 | - | $492.19M(-46.2%) |
| Dec 2000 | $914.22M(+50.3%) | $914.22M(+4.1%) |
| Sep 2000 | - | $878.12M(+4.5%) |
| Jun 2000 | - | $840.15M(+23.4%) |
| Mar 2000 | - | $680.89M(+12.0%) |
| Dec 1999 | $608.10M(+92.9%) | $608.10M(+14.5%) |
| Sep 1999 | - | $531.07M(+53.6%) |
| Jun 1999 | - | $345.78M(-1.7%) |
| Mar 1999 | - | $351.76M(+11.6%) |
| Dec 1998 | $315.20M(+37.0%) | $315.20M(+41.0%) |
| Sep 1998 | - | $223.47M(-11.2%) |
| Jun 1998 | - | $251.77M(+11.6%) |
| Mar 1998 | - | $225.54M(-1.9%) |
| Dec 1997 | $230.00M(+108.7%) | $230.00M(+77.7%) |
| Sep 1997 | - | $129.40M(+2.3%) |
| Jun 1997 | - | $126.52M(-5.6%) |
| Mar 1997 | - | $134.09M(+21.7%) |
| Dec 1996 | $110.20M(-60.8%) | $110.20M(-21.2%) |
| Sep 1996 | - | $139.90M(+25.5%) |
| Jun 1996 | - | $111.48M(+26.8%) |
| Mar 1996 | - | $87.92M(-68.7%) |
| Dec 1995 | $281.20M(-3.1%) | $281.20M(-12.3%) |
| Sep 1995 | - | $320.80M(+26.1%) |
| Jun 1995 | - | $254.40M(+38.1%) |
| Mar 1995 | - | $184.21M(-36.5%) |
| Dec 1994 | $290.27M(-3.5%) | $290.27M(+30.7%) |
| Sep 1994 | - | $222.03M(+22.9%) |
| Jun 1994 | - | $180.60M(+5.6%) |
| Mar 1994 | - | $171.06M(-43.1%) |
| Dec 1993 | $300.68M(+157.9%) | $300.68M(+118.2%) |
| Sep 1993 | - | $137.80M(+367.1%) |
| Jun 1993 | - | $29.50M(-42.7%) |
| Mar 1993 | - | $51.50M(-55.8%) |
| Dec 1992 | $116.60M(+93.0%) | $116.60M(+328.7%) |
| Sep 1992 | - | $27.20M(-29.2%) |
| Jun 1992 | - | $38.40M(+70.7%) |
| Mar 1992 | - | $22.50M(-62.7%) |
| Dec 1991 | $60.40M(+77.6%) | $60.40M(+22.0%) |
| Sep 1991 | - | $49.50M(-14.2%) |
| Jun 1991 | - | $57.70M(+6.3%) |
| Mar 1991 | - | $54.30M(+59.7%) |
| Dec 1990 | $34.00M(+150.0%) | $34.00M(-71.1%) |
| Sep 1990 | - | $117.50M(+225.5%) |
| Jun 1990 | - | $36.10M(-52.9%) |
| Mar 1990 | - | $76.60M(+463.2%) |
| Dec 1989 | $13.60M(-97.7%) | $13.60M(-97.7%) |
| Dec 1988 | $582.60M(+12.1%) | $582.60M(+12.1%) |
| Dec 1987 | $519.90M(+8.0%) | $519.90M(+8.0%) |
| Dec 1986 | $481.60M(+10.1%) | $481.60M(+10.1%) |
| Dec 1985 | $437.50M(-2.1%) | $437.50M(-2.1%) |
| Dec 1984 | $447.10M | $447.10M |
FAQ
- What is Abbott Laboratories annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Abbott Laboratories?
- What is Abbott Laboratories annual cash & cash equivalents year-on-year change?
- What is Abbott Laboratories quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Abbott Laboratories?
- What is Abbott Laboratories quarterly cash & cash equivalents year-on-year change?
What is Abbott Laboratories annual cash & cash equivalents?
The current annual cash & cash equivalents of ABT is $7.62B
What is the all time high annual cash & cash equivalents for Abbott Laboratories?
Abbott Laboratories all-time high annual cash & cash equivalents is $18.62B
What is Abbott Laboratories annual cash & cash equivalents year-on-year change?
Over the past year, ABT annual cash & cash equivalents has changed by +$720.00M (+10.44%)
What is Abbott Laboratories quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ABT is $6.53B
What is the all time high quarterly cash & cash equivalents for Abbott Laboratories?
Abbott Laboratories all-time high quarterly cash & cash equivalents is $18.62B
What is Abbott Laboratories quarterly cash & cash equivalents year-on-year change?
Over the past year, ABT quarterly cash & cash equivalents has changed by +$248.00M (+3.95%)